NEW YORK (GenomeWeb News) – Exact Sciences said Tuesday that it has licensed worldwide rights to Hologic's Invader plus and real-time Invader detection chemistries for colorectal screening applications.
Terms of the agreement are not being disclosed by the firms.
The Invader chemistry was developed by Hologic subsidiary Third Wave Technologies, which formerly was run by Exact Sciences' current President and CEO Kevin Conroy, before it was acquired by Hologic for $580 million in July 2008.
Invader is a molecular diagnostics platform that Exact intends to couple with digital PCR technology it exclusively licensed from Johns Hopkins University. The Madison, Wis.-based firm is developing a stool-based DNA test for colorectal cancer screening.